Secondly, no significant decrease in PRMT5 protein levels was observed upon treatment with an mTOR inhibitor in MM, whereas this was previously reported in T-cell expansion in a murine multiple sclerosis model (Webb et al., 2019). This evidence concerns the gene PRMT5 and Miyoshi myopathy.